Even though human beings are, by far, the smartest species to ever grace the world, we never have all the answers at our disposal. Hence, to find these answers, we conceive some unique inroads along the way. This is easier said than done, as every inroad you come across will likely have its own shortcomings. Nevertheless, the dynamic will change big time once we discover technology. It’s not to say that technology doesn’t have any weaklings whatsoever, but when you look at everything we have achieved under the creation’s stewardship, all those loopholes become more than worthwhile. The same has been evident within every technological foray so far, including the one revolving around a certain medical sector. While healthcare’s link-up with technology had the masses doubtful like nothing else, we would come around eventually, and we’ll do so on the back of some unbelievable results. Turbo-charged by a fresh identity, the sector would go on to make a lot of noise, except even after achieving so much, it will continue treading upon its unprecedented trajectory. In fact, one recent funding should only take this revolution a step further.
3Spine, Inc., a U.S. medical device company developing total joint replacement for the lumbar spine, has successfully secured over $33 million in an oversubscribed Series C financing. According to certain reports, the company plans to dedicate the fresh funds towards a Phase 2 clinical study of the Balanced Back Total Joint Replacement in the United States. Structured around 3Spine’s MOTUS device, which is an implant used in the said replacement procedure, this Phase 2 study will deepen the company’s knowhow on how it can use a posterior approach to replace disc and facet joints function. Talking about the study’s design, it’s expected to have around 150 patients. Notably enough, these patients will arrive from 16 separate clinical sites that are stretched across 11 states in total.
If further details are to be believed, the procedure carries a good chance of treating various concerns, including leg pain, back pain, and spinal instability. Beyond that, it can also correct posture and restore movement by practically recreating the patient’s functional spinal unit. Assuming 3Spine’s technology ends up going all the way, it will cater to a market of over $5 billion, as so far, it has looked like the only alternative for a traditional, and hugely complicated, lumbar spinal infusion.
“I have watched this technology mature over 15 years to this point where it is now one of the most researched biomechanical devices in the history of spinal surgery. The capital we have raised through private sources is a testament to the opportunity. Like many people in America, I have personal experience with spinal fusion. We can do better. 3Spine’s motion-based approach has the ability to improve the daily lives of millions of people,” said Marc Peterman, CEO, 3Spine.
